162 related articles for article (PubMed ID: 21533858)
1. Implications of transcriptional factor, OCT-4, in human bladder malignancy and tumor recurrence.
Huang P; Chen J; Wang L; Na Y; Kaku H; Ueki H; Sasaki K; Yamaguchi K; Zhang K; Saika T; Nasu Y; Watanabe M; Kumon H
Med Oncol; 2012 Jun; 29(2):829-34. PubMed ID: 21533858
[TBL] [Abstract][Full Text] [Related]
2. Expression of hedgehog pathway components is associated with bladder cancer progression and clinical outcome.
He HC; Chen JH; Chen XB; Qin GQ; Cai C; Liang YX; Han ZD; Dai QS; Chen YR; Zeng GH; Zhu JG; Jiang FN; Zhong WD
Pathol Oncol Res; 2012 Apr; 18(2):349-55. PubMed ID: 21861243
[TBL] [Abstract][Full Text] [Related]
3. UHRF1 is associated with tumor recurrence in non-muscle-invasive bladder cancer.
Yang GL; Zhang LH; Bo JJ; Chen HG; Cao M; Liu DM; Huang YR
Med Oncol; 2012 Jun; 29(2):842-7. PubMed ID: 21611839
[TBL] [Abstract][Full Text] [Related]
4. OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer.
Atlasi Y; Mowla SJ; Ziaee SA; Bahrami AR
Int J Cancer; 2007 Apr; 120(7):1598-602. PubMed ID: 17205510
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor β (ERβ) is a novel prognostic marker of recurrence survival in non-muscle-invasive bladder cancer potentially by inhibiting cadherin switch.
Han B; Cui D; Jing Y; Hong Y; Xia S
World J Urol; 2014 Feb; 32(1):149-55. PubMed ID: 24616912
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2 expression in urinary bladder transitional cell carcinoma and its association with clinicopathological characteristics.
Tabriz HM; Olfati G; Ahmadi SA; Yusefnia S
Asian Pac J Cancer Prev; 2013; 14(8):4539-43. PubMed ID: 24083698
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical analysis of the role and relationship between Notch-1 and Oct-4 expression in urinary bladder carcinoma.
Abdou AG; El-Wahed MM; Kandil MA; Samaka RM; Elkady N
APMIS; 2013 Oct; 121(10):982-96. PubMed ID: 23594289
[TBL] [Abstract][Full Text] [Related]
8. The expression of thymidine phosphorylase is a prognostic predictor for the intravesical recurrence of superficial bladder cancer.
Nonomura N; Nakai Y; Nakayama M; Inoue H; Nishimura K; Hatanaka E; Arima R; Kishimoto T; Miki T; Kuroda H; Okuyama A
Int J Clin Oncol; 2006 Aug; 11(4):297-302. PubMed ID: 16937303
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of Sox2 expression in transurethral resection specimens in patients with T1 bladder cancer.
Ruan J; Wei B; Xu Z; Yang S; Zhou Y; Yu M; Liang J; Jin K; Huang X; Lu P; Cheng H
Med Oncol; 2013 Mar; 30(1):445. PubMed ID: 23307254
[TBL] [Abstract][Full Text] [Related]
10. Expression of Cancer Stem Cell Markers OCT4 and CD133 in Transitional Cell Carcinomas.
Sedaghat S; Gheytanchi E; Asgari M; Roudi R; Keymoosi H; Madjd Z
Appl Immunohistochem Mol Morphol; 2017 Mar; 25(3):196-202. PubMed ID: 26945449
[TBL] [Abstract][Full Text] [Related]
11. Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder.
Christoph F; Weikert S; Kempkensteffen C; Krause H; Schostak M; Miller K; Schrader M
Int J Cancer; 2006 Sep; 119(6):1396-402. PubMed ID: 16642478
[TBL] [Abstract][Full Text] [Related]
12. Expression profile of E-cadherin and N-cadherin in non-muscle-invasive bladder cancer as a novel predictor of intravesical recurrence following transurethral resection.
Muramaki M; Miyake H; Terakawa T; Kumano M; Sakai I; Fujisawa M
Urol Oncol; 2012; 30(2):161-6. PubMed ID: 20451421
[TBL] [Abstract][Full Text] [Related]
13. Snail immunohistochemical overexpression correlates to recurrence risk in non-muscle invasive bladder cancer: results from a longitudinal cohort study.
Santi R; Cai T; Nobili S; Galli IC; Amorosi A; Comperat E; Nesi G
Virchows Arch; 2018 Apr; 472(4):605-613. PubMed ID: 29525824
[TBL] [Abstract][Full Text] [Related]
14. T-cell immunoglobulin mucin-3 expression in bladder urothelial carcinoma: Clinicopathologic correlations and association with survival.
Yang M; Yu Q; Liu J; Fu W; Cao Y; Yu L; Shao S; Wang X; Niu H; Wang Y
J Surg Oncol; 2015 Sep; 112(4):430-5. PubMed ID: 26265374
[TBL] [Abstract][Full Text] [Related]
15. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
[TBL] [Abstract][Full Text] [Related]
16. Reduced immunohistochemical PTEN staining is associated with higher progression rate and recurrence episodes in non-invasive low-grade papillary urothelial carcinoma of the bladder.
Kulac I; Arslankoz S; Netto GJ; Ertoy Baydar D
Virchows Arch; 2018 Jun; 472(6):969-974. PubMed ID: 29368083
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor β (ERβ) is a novel prognostic marker of recurrence survival in non-muscle-invasive bladder cancer potentially by inhibiting cadherin switch.
Han B; Cui D; Jing Y; Hong Y; Xia S
World J Urol; 2012 Dec; 30(6):861-7. PubMed ID: 22238119
[TBL] [Abstract][Full Text] [Related]
18. Expression of cell-cycle regulatory proteins and their prognostic value in superficial low-grade urothelial cell carcinoma of the bladder.
Santos LL; Amaro T; Pereira SA; Lameiras CR; Lopes P; Bento MJ; Oliveira J; Criado B; Lopes CS
Eur J Surg Oncol; 2003 Feb; 29(1):74-80. PubMed ID: 12559081
[TBL] [Abstract][Full Text] [Related]
19. High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder.
Zhang Z; Zhang G; Kong C
Urol Oncol; 2013 Oct; 31(7):1222-30. PubMed ID: 22192978
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of α‑ and β‑Klotho in urothelial carcinoma of the bladder.
Hori S; Miyake M; Onishi S; Tatsumi Y; Morizawa Y; Nakai Y; Anai S; Tanaka N; Fujimoto K
Oncol Rep; 2016 Oct; 36(4):2117-25. PubMed ID: 27573985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]